Review greenlights systemic psoriasis therapies for over 65s
But there is a critical need for more evidence in this population, the authors say
Age alone should not limit use of systemic therapies in people aged over 65 with psoriasis, the authors of a systematic review say.
The Dutch researchers aimed to pull together the evidence for both conventional and biologic therapies for psoriasis in this age group, examining 31 studies including a total of almost 40,000 patients.
Overall, only limited data was available for specific agents and the quality of evidence was low for conventional therapies, they reported in JAMA